Antiphospholipid antibodies (aPL) are associated with neurological diseases such as stroke, migraine, epilepsy and dementia and are thus associated with both vascular and non-vascular neurological disease. We have therefore examined the possibility that these antibodies interact directly with neuronal tissue by studying the electrophysiological effects of aPL on a brain synaptosoneurosome preparation. IgG from patients with high levels of aPL and neurological involvement was purified by protein-G affinity chromatography as was control IgG pooled from ten sera with low levels of aPL. Synaptoneurosomes were purified from perfused rat brain stem. IgG from the patient with the highest level of aPL at a concentration equivalent to 1:5 serum dilution caused significant depolarization of the synaptoneurosomes as determined by accumulation of the lipophylic cation [3H]-tetraphenylphosphonium. IgG from this patient as well as IgG from two elderly patients with high levels of aPL were subsequently shown to permeabilize the synaptosomes to labeled nicotinamide adenine dinucleotide (NAD) and pertussis toxin-ADP-ribose transferase (PTX-A protein) as assayed by labeled ADP-ribosylation of G-proteins in the membranes. No such effects were seen with the control IgG. aPL may thus have the potential to disrupt neuronal function by direct action on nerve terminals. These results may explain some of the non-thromboembolic CNS manifestations of the antiphospholipid syndrome.
Harris EN et al. Anticardiolipin antibodies: detection by radio immunoassay and association with thrombosis in systemic lupus erythematosus . Lancet1983; 2: 1211–1214 .
2.
Harris EN , Gharavi AE , Hughes GR . Anti-phospholipid antibodies . Clin Rheum Dis1985; 11: 591–609 .
3.
Asherson RA , Cervera R , Piette J-C , Shoenfeld Y . The Antiphospholipid Syndrome. CRC Press: Boca Raton, Florida , 1996.
4.
Harris EN . Special report. The Second International Anti-Cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group . Am J Clin Pathol1990; 94: 476–484 .
5.
Rapaport SI , Ames SB , Duval BJ . A plasma coagulation defect in systemic lupus erythematosus arising from hypoprothrombinemia combined with antiprothrombinase activity . Blood1960; 15: 212–215 .
6.
Asherson RA et al. Multiple venous and arterial thromboses associated with the lupus anticoagulant and antibodies to cardiolipin in the absence of SLE . Rheumatol Int1985; 5: 91–93 .
7.
Hughes GR . Thrombosis, abortion, cerebral disease, and the lupus anticoagulant . Br Med J (Clin Res Ed)1983; 287: 1088–1089 .
8.
Levine SR et al. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome . Ann Neurol1995; 38: 119–124 .
9.
Robbins L . Migraine and anticardiolipin antibodies<Eth>case reports of 13 patients, and the prevalence of antiphospholipid antibodies in migraineurs . Headache1991; 31: 537–539 .
10.
Levine SR , Joseph R , D'Andrea G , Welch KM . Migraine and the lupus anticoagulant. Case reports and review of the literature . Cephalalgia1987; 7: 93–99 .
11.
Herranz MT et al. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus . Arthritis Rheum1994; 37: 568–571 .
12.
Inzelberg R , Korczyn AD . Lupus anticoagulant and late onset seizures [see comments] . Acta Neurol Scand1989; 79: 114–118 .
13.
Verrot D et al. Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy . Am J Med1997; 103: 33–37 .
14.
Cervera R et al. Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature . Medicine (Baltimore)1997; 76: 203–212 .
15.
Bouchez B et al. Chorea and systemic lupus erythematosus with circulating anticoagulant. 3 cases . Rev Neurol (Paris)1985; 141: 571–577 .
16.
Lubbe WF , Walker EB . Chorea gravidarum associated with circulating lupus anticoagulant: successful outcome of pregnancy with prednisone and aspirin therapy. Case report . Br J Obstet Gynaecol1983; 90: 487–490 .
17.
Inzelberg R , Bornstein NM , Reider I , Korczyn AD . The lupus anticoagulant and dementia in non-SLE patients . Dementia1992; 3: 140–145 .
18.
Van Horn G , Arnett FC , Dimachkie MM . Reversible dementia and chorea in a young woman with the lupus anticoagulant . Neurology1996; 46: 1599–1603 .
19.
Ceccaldi M , Harle JR , Sangla I , Poncet M . Progressive encephalopathy in antiphospholipid antibody syndrome . Presse Med1993; 22: 1313–1316 .
20.
Coull BM et al. Multiple cerebral infarctions and dementia associated with anticardiolipin antibodies . Stroke1987; 18: 1107–1112 .
21.
Asherson RA et al. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies . Ann Rheum Dis1987; 46: 605–611 .
22.
Moore PM . Evidence for bound antineuronal antibodies in brains of NZB/W mice . J Neuroimmunol1992; 38: 147–154 .
23.
Hess DC et al. Cognitive and neurologic deficits in the MRL/lpr mouse: a clinicopathologic study . J Rheumatol1993; 20: 610–617 .
24.
Szechtman H , Sakic B , Denburg JA . Behaviour of MRL mice: an animal model of disturbed behavior in systemic autoimmune disease . Lupus1997; 6: 223–229 .
25.
Schrott LM , Crnic LS . Anxiety behavior, exploratory behavior, and activity in NZB6NZW F1 hybrid mice: role of genotype and autoimmune disease progression . Brain Behav Immun1996; 10: 260–274 .
26.
Aron AL et al. Early onset of autoimmunity in MRL= / / mice following immunization with beta 2 glycoprotein I . Clin Exp Immunol1995; 101: 78–81 .
27.
Brey RL et al. Model for the neuromuscular complications of systemic lupus erythematosus . Lupus1995; 4: 209–212 .
28.
Ziporen L , Shoenfeld Y , Levy Y , Korczyn AD . Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model . J Clin Invest1997; 100: 613–619 .
29.
Galli M et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor [see comments] . Lancet1990; 335: 1544–1547 .
30.
McNeil HP , Simpson RJ , Chesterman CN , Krilis SA . Anti-phospho-lipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipo-protein H) . Proc Natl Acad Sci USA1990; 87: 4120–4124 .
31.
Cabral AR , Amigo MC , Cabiedes J , Alarcon-Segovia D . The antiphospholipid/cofactor syndromes: a primary variant with anti-bodies to beta 2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays . Am J Med1996; 101: 472–481 .
32.
Roubey RA . Immunology of the antiphospholipid antibody syndrome . Arthritis Rheum1996; 39: 1444–1454 .
33.
Galli M . Non beta 2-glycoprotein I cofactors for antiphospholipid antibodies . Lupus1996; 5: 388–392 .
34.
Hollingsworth EB et al. Biochemical characterization of a filtered synaptoneurosome preparation from guinea pig cerebral cortex: cyclic adenosine 30:50-monophosphate-generating systems, receptors, and enzymes . J Neurosci1985; 5: 2240–2253 .
35.
Cohen-Armon M , Sokolovsky M . Inhibition of pertussis toxin catalyzed ADP-ribosylation of G-proteins by membrane depolarization in rat brain synaptoneurosomes . Neurosci Lett1991; 126: 87–90 .
36.
Cohen-Armon M , Sokolovsky M . Depolarization-induced changes in the muscarinic receptor in rat brain and heart are mediated by pertussis-toxin-sensitive G-proteins . J Biol Chem1991; 266: 2595–2605 .
37.
Levy Y et al. Membranous nephropathy in primary antiphospholipid syndrome: description of a case and induction of renal injury in SCID mice . Hum Antibodies Hybridomas1996; 7: 91–96 .
38.
Cheng K et al. Measurement of membrane potentials (psi) of erythrocytes and white adipocytes by the accumulation of triphenylmethylphosphonium cation . J Membr Biol1980; 56: 191–201 .
39.
Price BE et al. Anti-phospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a beta 2-glycoprotein I-dependent manner . J Immunol1996; 157: 2201–2208 .
40.
Obringer AR , Rote NS , Walter A . Antiphospholipid antibody binding to bilayer-coated glass microspheres . J Immunol Methods1995; 185: 81–93 .
41.
Fanelli A et al. Flow cytometric detection of circulating activated platelets in primary antiphospholipid syndrome. Correlation with thrombocytopenia and anticardiolipin antibodies . Lupus1997; 6: 261–267 .
42.
Martinuzzo ME , Maclouf J , Carreras LO , Levy-Toledano S . Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation . Thromb Haemost1993; 70: 667–671 .
43.
Del Papa N et al. Relationship between anti-phospholipid and anti-endothelial cell antibodies III: beta 2 glycoprotein I mediates the antibody binding to endothelial membranes and induces the expression of adhesion molecules . Clin Exp Rheumatol1995; 13: 179–185 .
44.
Brey RL , Sakic B , Szechtman H , Denburg JA . Animal models for nervous system disease in systemic lupus erythematosus [In Process Citation] . Ann NY Acad Sci1997; 823: 97–106 .
45.
Stewart MW , Etches WS , Gordon PA . Antiphospholipid antibody-dependent C5b-9 formation . Br J Haematol1997; 96: 451–457 .
46.
Reik KBM , Day AJ . Structure–function relationship of the complement components . Immunol Today1989; 10: 177–180 .
